PURPOSE: The purpose was to determine the effects of recurrent breast cancer on health-related quality of life (HRQOL). METHODS: We administered the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BR23, McGill Quality of Life Questionnaire (MQOL), Beck Depression Inventory (BDI), and Brief Fatigue Inventory (BFI) to 152 women experiencing recurrence 1 year after being diagnosed with stage I to III breast cancer. We classified recurrent women as post-, ongoing-, and non-treatment group and performed multivariate-adjusted analyses in HRQOL comparisons with data available from disease-free survivors and general population. RESULTS: Groups not completing treatment were more symptomatic and had poorer functioning in HRQOL than the post-treatment group. Compared to the general population, the post-treatment group showed worse scores concerning role, cognitive, and social functioning, fatigue, and financial difficulties. The post-treatment group showed identical scores to disease-free survivors in most HRQOL domains; however, they reported less fatigue and depression than the disease-free group. Higher overall QOL was related to absence of comorbidity, completing treatment, being involved in decision making, no problems before surgery, and good overall medical care. CONCLUSION: Treatment completed, most degraded aspects of HRQOL in recurrent breast cancer women can return to levels observed in disease-free survivors.
PURPOSE: The purpose was to determine the effects of recurrent breast cancer on health-related quality of life (HRQOL). METHODS: We administered the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and QLQ-BR23, McGill Quality of Life Questionnaire (MQOL), Beck Depression Inventory (BDI), and Brief Fatigue Inventory (BFI) to 152 women experiencing recurrence 1 year after being diagnosed with stage I to III breast cancer. We classified recurrent women as post-, ongoing-, and non-treatment group and performed multivariate-adjusted analyses in HRQOL comparisons with data available from disease-free survivors and general population. RESULTS: Groups not completing treatment were more symptomatic and had poorer functioning in HRQOL than the post-treatment group. Compared to the general population, the post-treatment group showed worse scores concerning role, cognitive, and social functioning, fatigue, and financial difficulties. The post-treatment group showed identical scores to disease-free survivors in most HRQOL domains; however, they reported less fatigue and depression than the disease-free group. Higher overall QOL was related to absence of comorbidity, completing treatment, being involved in decision making, no problems before surgery, and good overall medical care. CONCLUSION: Treatment completed, most degraded aspects of HRQOL in recurrent breast cancerwomen can return to levels observed in disease-free survivors.
Authors: M Hanson Frost; V J Suman; T A Rummans; A M Dose; M Taylor; P Novotny; R Johnson; R E Evans Journal: Psychooncology Date: 2000 May-Jun Impact factor: 3.894
Authors: C Hürny; J Bernhard; A S Coates; M Castiglione-Gertsch; H F Peterson; R D Gelber; J F Forbes; C M Rudenstam; E Simoncini; D Crivellari; A Goldhirsch; H J Senn Journal: Lancet Date: 1996-05-11 Impact factor: 79.321
Authors: S H Ahn; B W Park; D Y Noh; S J Nam; E S Lee; M K Lee; S H Kim; K M Lee; S M Park; Y H Yun Journal: Ann Oncol Date: 2006-10-09 Impact factor: 32.976
Authors: V M Duric; M R Stockler; S Heritier; F Boyle; J Beith; A Sullivan; N Wilcken; A S Coates; R J Simes Journal: Ann Oncol Date: 2005-08-26 Impact factor: 32.976
Authors: Richard M Hoffman; William C Hunt; Frank D Gilliland; Robert A Stephenson; Arnold L Potosky Journal: Cancer Date: 2003-04-01 Impact factor: 6.860
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Sareh Keshavarzi; Seyyed Mohammad Taghi Ayatollahi; Najaf Zare; Farkhondeh Sharif Journal: Qual Life Res Date: 2012-08-18 Impact factor: 4.147
Authors: Melissa S Y Thong; Floortje Mols; Jan-Willem W Coebergh; Jan A Roukema; Lonneke V van de Poll-Franse Journal: J Cancer Surviv Date: 2009-06-26 Impact factor: 4.442